Laurus Labs First Quarter 2025 Earnings: Misses Expectations

Laurus Labs (NSE:LAURUSLABS) First Quarter 2025 Results

Key Financial Results

• Revenue: ₹12.0b (up 1.3% from 1Q 2024).
• Net income: ₹125.1m (down 50% from 1Q 2024).
• Profit margin: 1.0% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses.
• EPS: ₹0.23 (down from ₹0.46 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Laurus Labs Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 89%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 2.0% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Laurus Labs (1 is potentially serious!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com